Clinical implications of 10-formyltetrahydrofolate dehydrogenase expression in hormone receptor-positive breast cancer
-
By
-
Han Suk Ryu
-
Amira A. Abdellatef
-
Da Sol Kim
-
Ilias P. Nikas
-
Sergey A. Krupenko
-
May 25, 2026
-
Clinical Scorecard: The Role of 10-Formyltetrahydrofolate Dehydrogenase Expression in Hormone Receptor-Positive Breast Cancer: Clinical Insights
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | ALDH1L1 expression and its role in folate metabolism and tumor suppression |
| Target Population | |
| Care Setting | |
Key Highlights
- ALDH1L1 expression is higher in non-tumor tissues compared to cancer tissues, particularly in luminal A subtypes.
- Higher ALDH1L1 expression correlates with smaller tumor size and lower tumor grade, especially in hormone receptor-positive subtypes.
Guideline-Based Recommendations
Diagnosis
- Assess ALDH1L1 expression in breast cancer tissues for prognostic evaluation, supported by recent studies.
Management
- Consider ALDH1L1 as a therapeutic target in hormone receptor-positive breast cancer, referencing ongoing clinical trials.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Therapeutic strategies may include restoring ALDH1L1 expression or using agents that enhance its activity.
Clinical Best Practices
- Incorporate ALDH1L1 expression analysis in routine pathology assessments and recommend follow-up studies to validate its role.
Related Resources & Content
